Clinical trial
A 12-week, Double-blind, International, Multicenter, Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
NCT00989963 is registered in ClinicalTrials.gov with Lung Biotechnology PBC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 12-week, Double-blind, International, Multicenter, Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Lung Biotechnology PBC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 1, 2010
- Completion date
- September 13, 2011
- Enrollment
- 36 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.